Evidence map›Paper›PMID 36366393›Full record

ArticleVaccines2022

Who Is at Higher Risk of SARS-CoV-2 Reinfection? Results from a Northern Region of Italy.

Maria Francesca Piazza, Daniela Amicizia, Francesca Marchini, Matteo Astengo, Federico Grammatico, Alberto Battaglini, Camilla Sticchi, Chiara Paganino, Rosa Lavieri, Giovanni Battista Andreoli and 3 more

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. SARS-CoV-2 reinfection rate before and after VOC Omicron emergence: a retrospective study in Brazil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Maria Francesca PiazzaRegional Health Agency of Liguria (ALiSa), 16121 Genoa, Italy.ORCID 0000-0002-2404-3609
Daniela AmiciziaRegional Health Agency of Liguria (ALiSa), 16121 Genoa, Italy.
Francesca MarchiniRegional Health Agency of Liguria (ALiSa), 16121 Genoa, Italy.
Matteo AstengoRegional Health Agency of Liguria (ALiSa), 16121 Genoa, Italy.
Federico GrammaticoRegional Health Agency of Liguria (ALiSa), 16121 Genoa, Italy.
Alberto BattagliniRegional Health Agency of Liguria (ALiSa), 16121 Genoa, Italy.
Camilla SticchiRegional Health Agency of Liguria (ALiSa), 16121 Genoa, Italy.
Chiara PaganinoRegional Health Agency of Liguria (ALiSa), 16121 Genoa, Italy.
Rosa LavieriRegional Health Agency of Liguria (ALiSa), 16121 Genoa, Italy.
Giovanni Battista AndreoliRegional Health Agency of Liguria (ALiSa), 16121 Genoa, Italy.
Andrea OrsiDepartment of Health Sciences (DiSSal), University of Genoa, 16132 Genoa, Italy.ORCID 0000-0002-2433-9610
Giancarlo IcardiDepartment of Health Sciences (DiSSal), University of Genoa, 16132 Genoa, Italy.ORCID 0000-0002-8463-8487
Filippo AnsaldiRegional Health Agency of Liguria (ALiSa), 16121 Genoa, Italy.
Agenzia Regionale per la Protezione dell'ambiente ligure · ITOspedale Policlinico San Martino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The SARS-CoV-2 pandemic continues to spread worldwide, generating a high impact on healthcare systems. The aim of the study was to examine the epidemiological burden of SARS-CoV-2 reinfections and to identify potential related risk factors. A retrospective observational study was conducted in Liguria Region, combining data from National Vaccines Registry and Regional Chronic Condition Data Warehouse. In the study period (September 2021 to May 2022), 335,117 cases of SARS-CoV-2 infection were recorded in Liguria, of which 15,715 were reinfected once. During the Omicron phase (which predominated from 3 January 2022), the risk of reinfection was 4.89 times higher (p < 0.001) than during the Delta phase. Unvaccinated and vaccinated individuals with at least one dose for more than 120 days were at increased risk of reinfection compared with vaccinated individuals with at least one dose for ≤120 days, respectively (odds ratio (OR) of 1.26, p < 0.001; OR of 1.18, p < 0.001). Healthcare workers were more than twice as likely to be reinfected than non-healthcare workers (OR of 2.38, p < 0.001). Lower ORs were seen among people aged 60 to 79 years. Two doses or more of vaccination were found to be protective against the risk of reinfection rather than a single dose (mRNA vaccines: OR of 0.06, p < 0.0001, and OR of 0.1, p < 0.0001; vector vaccines: OR of 0.05, p < 0.0001). Patients with chronic renal failure, cardiovascular disease, bronchopneumopathy, neuropathy and autoimmune diseases were at increased risk of reinfection (OR of 1.38, p = 0.0003; OR of 1.09, p < 0.0296; OR of 1.14, p = 0.0056; OR of 1.78, p < 0.0001; OR of 1.18, p = 0.0205). Estimating the epidemiological burden of SARS-CoV-2 reinfections and the role played by risk factors in reinfections is relevant for identifying risk-based preventive strategies in a pandemic context characterized by a high circulation of the virus and a high rate of pathogen mutations.

Indexed as

comorbiditiesCOVID-19epidemiological burdenrisk factorSARS-CoV-2vaccinationvaccine

Identifiers

PMID36366393
PMCPMC9692964
OpenAlexW4308717746

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.